InflaRx (IFRX) Tax Provisions (2024 - 2025)
InflaRx's (IFRX) quarterly Tax Provisions came in at -$14358.3 in Q3 2025, down 150.61% year-over-year from $28371.9 in Q3 2024, and down 157.55% quarter-over-quarter from -$5574.9 in Q4 2024.
Powered by 
Analysis
InflaRx (IFRX) Tax Provisions (2024 - 2025) Analysis & Trends
InflaRx has disclosed Tax Provisions across 2 years of filings, most recently posting -$14358.3 for Q3 2025.
- In Q3 2025, Tax Provisions fell 150.61% year-over-year to -$14358.3; the TTM figure through Dec 2025 stood at -$25662.6 (down 127.02% YoY), while the FY2025 annual figure was -$13876.3, down 148.91% from the prior year.
- Tax Provisions came in at -$14358.3 for Q3 2025 at InflaRx, down from -$5574.9 in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of -$5574.9 in Q4 2024 to a low of -$14358.3 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -3.96 Mn |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -14,358.33 |
| Dec 31, 2024 | -5,574.86 |
| Sep 30, 2024 | -5,729.41 |